NCT02638909: Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies |
|
|
| Terminated | 2 | 4 | US | ceritinib, Zykadia | Criterium, Inc., University of Colorado, Denver, Novartis | Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma | 03/18 | 03/18 | | |